Načítá se...
Varenicline Ameliorates Nicotine Withdrawal-Induced Learning Deficits in C57BL/6 Mice
Varenicline a partial agonist for α4β2 nicotinic acetylcholine receptors (nAChRs) and full agonist for α7 nAChRs, has been approved for the treatment of smoking cessation. While recent clinical trials support the efficacy of varenicline for managing global nicotine withdrawal symptoms and for smokin...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2683368/ https://ncbi.nlm.nih.gov/pubmed/18823172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1037/a0012601 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|